Peter A. Minchella

Peter A. Minchella

Auto-generated profile, based on publicly available information

Peter A. Minchella

Affiliation U.S. Centers for Disease Control and Prevention Division of Global HIV/TB, Center for Global Health, Lusaka, Zambia

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2014 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
PMPeter A. Minchella
Peter A. Minchella
SDSimon Donkor
Simon Donkor
OOOlumuyiwa Owolabi
Olumuyiwa Owolabi
JSJayne S. Sutherland
Jayne S. Sutherland
JMJoann M. McDermid
Joann M. McDermid
Background. Anemia is common in tuberculosis, and multiple etiologies necessitate targeted interventions. The proportion of iron-responsive anemia due to iron deficiency compared with iron-unresponsive anemia due to impaired iron absorption/redistribution from tuberculosis-associated immune activation or inflammation is unknown. This impedes selection of safe and effective treatment and appropriate intervention timing.

4 June 2021 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Open access
DCDuncan Chanda
Duncan Chanda
PMPeter A. Minchella
Peter A. Minchella
DKDavies Kampamba
Davies Kampamba
MIMegumi Itoh
Megumi Itoh
JHJonas Z. Hines
Jonas Z. Hines
LMLloyd B. Mulenga
Lloyd B. Mulenga
This report describes how HIV-positive patients with severe HIV disease were more likely to develop severe COVID-19 or die of COVID-19.

1 June 2015 in The Journal of Nutrition
Verified
Journal Article
Open access
PDF file
PMPeter A Minchella
Peter A Minchella
AAAndrew Armitage
Andrew Armitage
BDBakary Darboe
Bakary Darboe
MJMomodou W Jallow
Momodou W Jallow
HDHal Drakesmith
Hal Drakesmith
JMJoann M McDermid
Joann M McDermid
Background: Early and chronic inflammation is a hallmark of HIV infection, and inflammation is known to increase hepcidin expression. Consequently, he

24 February 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PMPeter A. Minchella
Peter A. Minchella
GCGeoffrey Chipungu
Geoffrey Chipungu
AKAndrea A. Kim
Andrea A. Kim
ASAbdoulaye Sarr
Abdoulaye Sarr
HAHammad Ali
Hammad Ali
DSDaniel Singer
Daniel Singer
Efforts to reach UNAIDS’ treatment and viral suppression targets have increased demand for viral load (VL) testing and strained existing laboratory networks, affecting turnaround time. Longer VL turnaround times delay both initiation of formal adherence counseling and switches to second-line therapy for persons failing treatment and contribute to poorer health outcomes. We utilized descriptive statistics and logistic regression to analyze VL testing data collected in Malawi between January 2013 and March 2016. The primary outcomes assessed were greater-than-median pretest phase turnaround time (days elapsed from specimen collection to receipt at the laboratory) and greater-than-median test phase turnaround time (days from receipt to testing). The median number of days between specimen collection and testing increased 3-fold between 2013 (8 days, interquartile range (IQR) = 6–16) and 2015 (24, IQR = 13–39) (p<0.001). Multivariable analysis indicated that the odds of longer pretest phase turnaround time were significantly higher for specimen collection districts without laboratories capable of conducting viral load tests (adjusted odds ratio (aOR) = 5.16; 95% confidence interval (CI) = 5.04–5.27) as well as for Malawi’s Northern and Southern regions. Longer test phase turnaround time was significantly associated with use of dried blood spots instead of plasma (aOR = 2.30; 95% CI = 2.23–2.37) and for certain testing months and testing laboratories. Increased turnaround time for VL testing appeared to be driven in part by categorical factors specific to the phase of turnaround time assessed. Given the implications of longer turnaround time and the global effort to scale up VL testing, addressing these factors via increasing efficiencies, improving quality management systems and generally strengthening the VL spectrum should be considered essential components of controlling the HIV epidemic.

1 November 2014 in The International Journal of Tuberculosis and Lung Disease
Verified
Journal Article
Closed access
PMP. A. Minchella
P. A. Minchella
AAAndrew Armitage
Andrew Armitage
BDB. Darboe
B. Darboe
MJM. W. Jallow
M. W. Jallow
HDH. Drakesmith
H. Drakesmith
JMJ. M. McDermid
J. M. McDermid
Hepcidin inhibits ferroportin-mediated iron efflux, leading to intracellular macrophage iron retention, possibly favoring Mycobacterium tuberculosis iron acquisition and tuberculosis (TB) pathogenesis. Plasma hepcidin was measured at human immunodeficiency virus (HIV) diagnosis in a retrospective HIV-prevalent, antiretroviral-naïve African cohort to investigate the association with incident pulmonary and/or extra-pulmonary TB. One hundred ninety-six participants were followed between 5 August 1992 and 1 June 2002, with 32 incident TB cases identified. Greater hepcidin was associated with significantly increased likelihood of TB after a median time to TB of 6 months. Elucidation of iron-related causal mechanisms and time-sensitive biomarkers that identify individual changes in TB risk are needed.

1 May 2015 in Tuberculosis
Verified
Journal Article
Closed access
PMPeter A. Minchella
Peter A. Minchella
SDSimon Donkor
Simon Donkor
JMJoann M. McDermid
Joann M. McDermid
JSJayne S. Sutherland
Jayne S. Sutherland